King Pharma (KG) Beat Q3 Views by 2c
King Pharmaceuticals (NYSE: KG) reports Q3 EPS of $0.29, 2 cents better than the analyst estimate of $0.27. Revenue for the quarter was $463 million, which compares to the estimate of $444.98 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
- Talbots, Inc. (TLB) Posts Surprise Q1 Profit; Comps Dip 3.8%
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
